#United States #Tallahassee #Trulieve #Cannabis #financial results

Trulieve Reports Profitable First Quarter 2026 Results

Trulieve Cannabis Corp., established as a leading cannabis company in the United States, shared its financial results for the first quarter of 2026, revealing impressive metrics that illustrate the company's robust performance. The report, made public on May 7, 2026, indicates a revenue of $287 million, with 59% gross margin, driven mainly by retail sales, which accounted for 92% of total revenue.

Financial Highlights

• - Net Income: Trulieve has achieved a positive net income attributable to common shareholders of $2 million. This shows a significant recovery from the previous year's loss and underscores the company’s successful strategies in managing costs and boosting revenues. Adjusted net income, which accounts for non-recurring items and impairments, rose to $20 million.
• - Adjusted EBITDA: The adjusted EBITDA for this quarter reached $100 million, representing 35% of total revenue, indicating a strong operational efficiency.
• - Cash Flow: The company generated $56 million in cash flow from operations, with free cash flow standing at $42 million, enabling further investment into growth initiatives.
• - Assets: Ending the quarter with $353 million in cash, Trulieve is well-positioned for future expansions and operational improvements.

The company also executed a $60 million private placement of senior secured notes, aiming to solidify its financial position and fund growth opportunities.

Expansion Initiatives

During this quarter, Trulieve opened three new dispensaries in Florida, increasing its retail footprint to 240 locations across the United States. This expansion not only increases access for customers but also takes advantage of the growing demand for cannabis products.

Additionally, the company has successfully grown its rewards program to 1 million members, enhancing customer loyalty and engagement, which is essential for maintaining a competitive edge in a rapidly evolving market.

Regulatory Changes Impacting Business

Another pivotal development impacting Trulieve’s operations is the recent rescheduling of medical marijuana to Schedule III. This alteration, announced by the Trump Administration, allows the company to expedite applications for DEA registration for its licensed medical marijuana operations. Trulieve has already filed applications for 206 retail locations with the DEA, which could facilitate further market expansion and operational efficiency.

Kim Rivers, the CEO of Trulieve, expressed enthusiasm regarding these changes, stating, “We applaud President Trump and AG Blanche for taking bold, decisive action to reclassify medical marijuana to Schedule III. With our extensive production capabilities and retail presence, we're well-positioned to seize new opportunities resulting from this rescheduling.”

Conclusion

Trulieve Cannabis Corp.’s Q1 2026 report highlights a strong foundation for the company amidst a challenging industry landscape. Increased revenues, tightened operational costs, and expanding market presence showcase Trulieve's strategic focus and adaptive measures in the evolving cannabis sector. As the regulatory environment adjusts and demand continues to grow, Trulieve is poised for further success in the coming months.